D. Shortridge

发表

Rapid Clinical Bacteriology and Its Future Impact

J. Schrenzel, A. van Belkum, W. Dunne, 2012, Annals of laboratory medicine.

Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa

Jean-Baptiste Veyrieras, Alex van Belkum, Daniel Brami, 2015, mBio.

Characterization and Prevalence of MefA, MefE, and the Associated msr(D) Gene in Streptococcus pneumoniae Clinical Isolates

S. Doktor, D. Shortridge, R. Flamm, 2004, Journal of Clinical Microbiology.

Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections

D. Shortridge, R. Flamm, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves

P. Rhomberg, D. Shortridge, R. Flamm, 2019, Antimicrobial Agents and Chemotherapy.

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori

D. Graham, J. Versalovic, D. Shortridge, 1997, Antimicrobial agents and chemotherapy.

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori

D. Graham, J. Versalovic, D. Shortridge, 1996, Antimicrobial agents and chemotherapy.

Identification of a 23S rRNA Gene Mutation in Clarithromycin‐Resistant Helicobacter pylori

J. Versalovic, D. Shortridge, R. Flamm, 1996, Helicobacter.

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

M. Castanheira, D. Shortridge, R. Mendes, 2022, Microbiology spectrum.

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

M. Castanheira, D. Shortridge, S. Arends, 2021, Antimicrobial agents and chemotherapy.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016–19)

M. Castanheira, M. Huband, D. Shortridge, 2021, JAC-antimicrobial resistance.

Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe

D. Shortridge, C. Carvalhaes, H. Sader, 2020, Antimicrobial Agents and Chemotherapy.

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018

M. Huband, M. Pfaller, D. Shortridge, 2020, Antimicrobial Agents and Chemotherapy.

Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against Pseudomonas aeruginosa From ICU Patients With Bloodstream Infections or Pneumonia

M. Pfaller, D. Shortridge, R. Flamm, 2019, Open Forum Infectious Diseases.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates

M. Castanheira, M. Pfaller, D. Shortridge, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018

M. Castanheira, M. Pfaller, D. Shortridge, 2019, Antimicrobial Agents and Chemotherapy.

Comparison of Three Reference Methods for Testing Susceptibility of Staphylococci to Trimethoprim-Sulfamethoxazole

W. Dunne, D. Creely, D. Shortridge, 2009, Journal of Clinical Microbiology.

Antimicrobial Susceptibilities of Invasive Pediatric Abiotrophia and Granulicatella Isolates

A. Freeman, S. Shulman, D. Shortridge, 2004, Journal of Clinical Microbiology.

Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.

F. Aarestrup, P. McDermott, L. Piddock, 2004, Microbial drug resistance.

Correlation of Cefoxitin MICs with the Presence of mecA in Staphylococcus spp

B. Zimmer, M. Weinstein, S. McAllister, 2009, Journal of Clinical Microbiology.

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020

M. Castanheira, D. Shortridge, C. Carvalhaes, 2021, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial.

D. Shortridge, R. Flamm, G. Stone, 1997, The Journal of antimicrobial chemotherapy.

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.

M. Castanheira, D. Shortridge, C. Carvalhaes, 2019, Diagnostic microbiology and infectious disease.

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018).

D. Shortridge, C. Carvalhaes, R. Flamm, 2020, Diagnostic microbiology and infectious disease.

Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe

M. Castanheira, D. Shortridge, L. Deshpande, 2022, JAC-antimicrobial resistance.

Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016–2018)

M. Castanheira, M. Pfaller, D. Shortridge, 2022, Infection and drug resistance.

OP-JANM210254 2600..2605

M. Castanheira, D. Shortridge, C. Carvalhaes, 2021 .

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.

M. Pfaller, D. Shortridge, R. Flamm, 2020, Diagnostic microbiology and infectious disease.

Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.

M. Castanheira, M. Pfaller, D. Shortridge, 2017, Microbial drug resistance.

Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015

M. Castanheira, M. Pfaller, D. Shortridge, 2017, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)

M. Castanheira, M. Huband, D. Shortridge, 2022, European Journal of Clinical Microbiology & Infectious Diseases.

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

D. Graham, J. Versalovic, M. Dore, 1997, The Journal of antimicrobial chemotherapy.

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli

G. Weinstock, E. Sodergren, Lei Chen, 2018, mBio.

Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline

A. Matlow, Steven D. Brown, D. Talkington, 2011 .

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016

M. Castanheira, D. Shortridge, H. Sader, 2017, Antimicrobial Agents and Chemotherapy.

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018

M. Castanheira, D. Shortridge, R. Mendes, 2019, Antimicrobial Agents and Chemotherapy.

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Zervos, M. Pfaller, 2019, Open forum infectious diseases.

Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, Enterococcus faecalis, and Staphylococcus Species

A. van Belkum, S. Gatermann, J. Meece, 2022, Journal of clinical microbiology.

Activity of fosfomycin when tested against US contemporary bacterial isolates.

P. Rhomberg, D. Shortridge, R. Flamm, 2019, Diagnostic microbiology and infectious disease.

GENOMIC RESISTANCE GENE DETECTION, INTEGRON DIVERSITY MAPPING AND RESISTOME-WIDE ASSOCIATION ANALYSIS HELP DEFINE ANTIBIOTIC RESISTANCE IN PSEUDOMONAS AERUGINOSA

J. Veyrieras, D. Creely, W. Dunne, 2018 .

Correlation between phenotypic antibiotic susceptibility and the resistome in Pseudomonas aeruginosa.

Jean-Baptiste Veyrieras, Alex van Belkum, Stéphane Schicklin, 2017, International journal of antimicrobial agents.

Antimicrobial performance of two preoperative skin preparation solutions containing iodine and isopropyl alcohol.

M. Bashir, C. Deeken, S. Lake, 2021, American journal of infection control.

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillanc

M. Castanheira, M. Pfaller, D. Shortridge, 2018, Diagnostic microbiology and infectious disease.

Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997–2016

Ronald N. Jones, A. Tsakris, M. Huband, 2019, Open forum infectious diseases.

Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in an Era of Drug-Resistant Streptococcus pneumoniae

T. Busman, D. Shortridge, G. Notario, 2003, Clinical drug investigation.

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.

D. Shortridge, C. Carvalhaes, H. Sader, 2020, The Journal of antimicrobial chemotherapy.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).

M. Castanheira, M. Pfaller, D. Shortridge, 2017, Journal of global antimicrobial resistance.

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015)

M. Castanheira, M. Pfaller, D. Shortridge, 2019, Journal of chemotherapy.

International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests

W. Dunne, A. van Belkum, D. Creely, 2013, European Journal of Clinical Microbiology & Infectious Diseases.

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).

M. Castanheira, M. Pfaller, D. Shortridge, 2017, International journal of antimicrobial agents.

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

M. Pfaller, K. Hamed, D. Shortridge, 2019, Diagnostic microbiology and infectious disease.

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015

M. Castanheira, D. Shortridge, H. Sader, 2017, Antimicrobial Agents and Chemotherapy.

Telavancin Activity Against a Global Collection of Staphylococcus aureus Clinical Isolates (2013–2015)

M. Castanheira, D. Shortridge, R. Mendes, 2017 .

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program

M. Huband, M. Pfaller, D. Shortridge, 2018, Antimicrobial Agents and Chemotherapy.

Surveillance of omadacycline activity tested against clinical isolates from the United States: Report from the SENTRY Antimicrobial Surveillance Program, 2019: Omadacycline 2019 Surveillance - USA.

M. Huband, M. Pfaller, D. Shortridge, 2021, Journal of global antimicrobial resistance.

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.

M. Huband, M. Pfaller, D. Shortridge, 2019, Journal of global antimicrobial resistance.

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients

M. Castanheira, D. Shortridge, H. Sader, 2017, Open Forum Infectious Diseases.

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018

M. Castanheira, D. Shortridge, C. Carvalhaes, 2020, Antimicrobial Agents and Chemotherapy.

1272. Cefiderocol In Vitro Activity Against Molecularly Characterized Acinetobacter baumannii-calcoaceticus Complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in United States Hospitals (2020)

M. Castanheira, D. Shortridge, H. Sader, 2021, Open Forum Infectious Diseases.

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19)

M. Castanheira, D. Shortridge, C. Carvalhaes, 2021, The Journal of antimicrobial chemotherapy.

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.

M. Pfaller, D. Shortridge, R. Flamm, 2019, International Journal of Antimicrobial Agents.

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates

M. Castanheira, D. Shortridge, Valerie Kantro, 2023, Microbiology spectrum.

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program.

M. Pfaller, D. Shortridge, R. Flamm, 2020, Journal of global antimicrobial resistance.

Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division

M. Pfaller, D. Shortridge, R. Flamm, 2017, Open Forum Infectious Diseases.

Ceftolozane-Tazobactam Activity Against Clinical Isolates of Pseudomonas aeruginosa from ICU Patients with Pneumonia: United States, 2015-2018.

M. Pfaller, D. Shortridge, H. Sader, 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin

D. Shortridge, R. Flamm, D. Stamler, 1997, Epidemiology and Infection.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

M. Castanheira, M. Pfaller, D. Shortridge, 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019).

M. Pfaller, D. Shortridge, R. Flamm, 2020, Journal of global antimicrobial resistance.

Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program

M. Huband, M. Pfaller, D. Shortridge, 2017, Open Forum Infectious Diseases.

In Vitro Evaluation of Delafloxacin Activity when Tested Against Contemporary community-Acquired Bacterial Respiratory Tract Infection Isolates (2014–2016): Results from the Sentry Antimicrobial Surveillance Program

M. Huband, P. Rhomberg, D. Shortridge, 2017, Open Forum Infectious Diseases.

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone

M. Pfaller, R. Jones, D. Shortridge, 2018, Journal of Clinical Microbiology.

Population Analysis of Escherichia coli Isolates with Discordant Resistance Levels by Piperacillin-Tazobactam Broth Microdilution and Agar Dilution Testing

A. van Belkum, D. Creely, W. Dunne, 2013, Antimicrobial Agents and Chemotherapy.

International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests

W. Dunne, D. Creely, M. Peyret, 2013, European Journal of Clinical Microbiology & Infectious Diseases.